<code id='1D901F14D3'></code><style id='1D901F14D3'></style>
    • <acronym id='1D901F14D3'></acronym>
      <center id='1D901F14D3'><center id='1D901F14D3'><tfoot id='1D901F14D3'></tfoot></center><abbr id='1D901F14D3'><dir id='1D901F14D3'><tfoot id='1D901F14D3'></tfoot><noframes id='1D901F14D3'>

    • <optgroup id='1D901F14D3'><strike id='1D901F14D3'><sup id='1D901F14D3'></sup></strike><code id='1D901F14D3'></code></optgroup>
        1. <b id='1D901F14D3'><label id='1D901F14D3'><select id='1D901F14D3'><dt id='1D901F14D3'><span id='1D901F14D3'></span></dt></select></label></b><u id='1D901F14D3'></u>
          <i id='1D901F14D3'><strike id='1D901F14D3'><tt id='1D901F14D3'><pre id='1D901F14D3'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:focus    - browse:84441
          Darron Cummings/AP

          Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

          The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

          advertisement

          Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus